Glycolytic reprogramming in cancer: immune crosstalk, nutrient competition, and supportive care perspectives - Top-Institutions - MDSpire

Glycolytic reprogramming in cancer: immune crosstalk, nutrient competition, and supportive care perspectives

  • By

  • Hui Wu

  • Yan Wang

  • Yu Tian

  • Shipin Feng

  • Xiongtao Yang

  • Xiaoli Yuan

  • Linlin Fan

  • Qiang Feng

  • Zhaoxia Liu

  • Qi Zhao

  • June 8, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    The University of Texas MD Anderson Cancer Center
    The University of Texas MD Anderson Cancer Center

    Houston, Texas

    Key Differentiators

    • Oncology
    • Immunology
    • Metabolic Research

  • #2

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, New York

    Key Differentiators

    • Oncology
    • Surgical Oncology
    • Radiation Oncology

  • #3

    Johns Hopkins University - Sidney Kimmel Comprehensive Cancer Center
    Johns Hopkins University - Sidney Kimmel Comprehensive Cancer Center

    Baltimore, Maryland

    Key Differentiators

    • Oncology
    • Molecular Biology
    • Immunology

  • #4

    University of California, Los Angeles (UCLA)
    University of California, Los Angeles (UCLA)

    Los Angeles, California

    Key Differentiators

    • Oncology
    • Clinical Research
    • Translational Medicine

  • #5

    University of Colorado School of Medicine
    University of Colorado School of Medicine

    Aurora, Colorado

    Key Differentiators

    • Oncology
    • Pediatric Oncology
    • Clinical Trials

Original Source(s)

Glycolytic reprogramming in cancer: immune crosstalk, nutrient competition, and supportive care perspectives

  • by Hui Wu, Yan Wang, Yu Tian, Shipin Feng, Xiongtao Yang, Xiaoli Yuan, Linlin Fan, Qiang Feng, Zhaoxia Liu, Qi Zhao

  • June 8, 2026

Related Content

Feasibility of weekly patient-reported symptom monitoring using patients' own smartphones in outpatient cancer chemotherapy: the SMART-PRO study

Tislelizumab combined with gemcitabine as first-line treatment in cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma: a single center, single-arm phase 2 trial

NAT10 as a central node in cancer biology: integrating epitranscriptomic regulation, metabolic reprogramming, and immune modulation